Company intelligence / Profile preview

GB001

San Diego, CA, USA

Ownership: Private
Employees: ~145
Development stage: Other

Overview

Gossamer Bio is currently focused on the Phase 3 development of its lead candidate seralutinib (GB002) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The registrational Phase 3 PROSERA study in PAH completed enrollment in June 2025, with topline results expected in February 2026. The namesake candidate GB001, a DP2 antagonist, failed to meet the primary endpoint in the Phase 2b LEDA study for asthma in 2020 and its development was subsequently deprioritized in favor of the pulmonary hypertension franchise.

Therapeutic areas: CardiovascularPulmonologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Chiesi FarmaceuticiMerckIMIDomicsAstellas Pharma

Beyond the preview

Go deeper on GB001.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB001.

Explore the full profile